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Abstract
Background Treatment of hereditary angioedema (HAE) in
‘older adults’ (those agedC65 years) has not been well studied.
The international Berinert Patient Registry collected data on the
use of intravenous plasma-derived, pasteurized, nanofiltered
C1-inhibitor concentrate (pnfC1-INH; Berinert/CSL Behr-
ing) in patients of any age, including many older adults.
Methods This observational registry, conducted from 2010
to 2014 at 30 US and seven European sites, gathered
prospective (post-enrollment) and retrospective (pre-en-
rollment) usage and adverse event (AE) data on subjects
treated with pnfC1-INH.
Results The registry documented 1701 pnfC1-INH infu-
sions in 27 older adults. A total of 1511 HAE attacks treated
with pnfC1-INH administration were reported among 25 of
the 27 (92.6 %) older adults. Among the older adults, mean
(standard deviation [SD]) (8.8 [4.1] IU/kg) and median
(6.4 IU/kg) pnfC1-INH doses were lower than those repor-
ted for 252 ‘younger adults’ (those aged \65 years: 12.9
[6.2], 12.5 IU/kg, respectively). A total of 19 AEs occurred
in 8 of 23 (34.8 %) older adults with prospective data, for
rates of 0.83 events per subject and 0.02 events per infusion,
similar to corresponding rates in younger adults (0.91 and
0.03, respectively). None of the AEs were considered related
to pnfC1-INH, and all but two events (prostatectomy, gas-
trointestinal bleeding) were mild or moderate in severity.
Administration of pnfC1-INH outside of a healthcare setting
was reported for 1609 infusions in 16 older adults, repre-
senting 94.6 % of all pnfC1-INH infusions in this age group.
There were no recorded instances of difficulty with self-
administration of intravenous pnfC1-INH.
Conclusions These findings suggest a high degree of safety
with intravenous pnfC1-INH use in older adults with HAE,
regardless of administration setting.
Trial Registration Clinicaltrials.gov NCT01108848.
Key Points
Published data and treatment recommendations
specific to the management of hereditary
angioedema (HAE) in older patients (aged
C65 years) are lacking.
The Berinert Patient Registry dataset included 27
older adults with HAE who used a combined total of
1701 Berinert (plasma-derived C1-inhibitor
concentrate) infusions.
In this subset of older adults using Berinert for HAE,
the rate of adverse events was low (0.02 events per
infusion), and a majority of infusions (94.6 %) were
administered outside of a healthcare setting, with no
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1 Introduction
Hereditary angioedema (HAE) is a rare, autosomal domi-
nant disorder characterized in most cases by a quantitative
and/or qualitative deficiency in the C1-inhibitor (C1-INH)
protein primarily due to genetic mutations [1, 2]. As C1-
INH is a key regulator of inflammation, inadequate activity
leads to unchecked activation of the classic complement
pathway and bradykinin system with subsequent vascular
leakage and angioedema. Clinically, presenting symptoms
include acute non-pruritic and recurrent episodes of local-
ized subcutaneous or submucosal swelling, often involving
the extremities, upper airways, and gastrointestinal (GI)
and urogenital tracts [1]. Laryngeal edema, while less
frequent, poses a serious risk for asphyxiation unless
properly treated [3, 4]. With the potential for high mor-
bidity and mortality, coupled with the unpredictable nature
of attacks, HAE can have a substantial effect on quality of
life for patients and their families [5–8].
Although HAE is commonly diagnosed during child-
hood or early adulthood [9, 10], the chronic nature of the
disease requires ongoing medical follow-up and treatment
throughout the patient’s entire lifespan, including into old
age. As treatment options for HAE have continued to
improve over recent decades, it is likely that many indi-
viduals are living longer and requiring continued treatment
well into later adulthood. In general, as patients age, it is
not uncommon for medical needs to shift because of
physiologic changes, higher rates of comorbidities, and
concomitant drug use [11]. Therefore, drug therapies are
often studied specifically in elderly populations to ensure
safety and appropriate usage in this demographic. With
regard to HAE management, current consensus guidelines
do not address issues specific to older adults, and there is a
gap in research regarding HAE management in this age
group, including general treatment strategies and outcomes
[12]. Furthermore, the current paradigm in HAE manage-
ment focuses heavily on administration outside of a
healthcare setting (home- or self-administration) [13–17],
but the technical and medical feasibility of this approach
has not yet been studied in older adult patients specifically
[12].
The plasma-derived, highly-purified, pasteurized,
nanofiltered C1-INH concentrate (pnfC1-INH; Berinert/
CSL Behring) is approved in the USA for the treatment of
HAE attacks in patients of all ages, and in the EU for the
treatment of HAE attacks and short-term prophylaxis in
adults and children. To evaluate the continued safety of
pnfC1-INH administration within the real-world setting,
the international Berinert Patient Registry (hereafter,
‘registry’) was designed to gather data on pnfC1-IHN
treatment across all age groups [18]. The final registry
dataset included a sufficient number of subjects aged
C65 years (hereafter, ‘older adults’) to allow for analysis
of usage patterns and safety in this population. This report




This multicenter observational patient registry
(NCT01108848) was conducted between 2010 and 2014 at
30 sites in the USA and seven sites in Europe (five in
Germany, one in Denmark, one in Switzerland). Retro-
spective (pnfC1-INH infusions given prior to registry
enrollment) and prospective (pnfC1-INH infusions given
after registry enrollment) data were captured by medical
chart review in accordance with local regulatory require-
ments pertaining to non-interventional studies. All subjects
provided informed consent for the collection of treatment
data prior to enrollment, allowing data to be gathered
willingly without impact on treatment decisions or a
patient’s choice to use pnfC1-INH. The study protocol and
master informed consent form were reviewed and approved
by relevant institutional review boards and institutional
ethics committees. Subject information was anonymized,
and project staff adhered to procedures to ensure the con-
fidentiality of all data as required by the guidelines of the
International Conference on Harmonization [19].
2.2 Subjects
Subjects enrolled in the registry included individuals of any
age who used pnfC1-INH for any reason, irrespective of
regionally approved product indication.
2.3 Data Collection
Both retrospective and prospective data on pnfC1-INH use
among enrolled subjects were obtained through chart re-
view. Subject data were documented in the subjects’
medical records by study site personnel and transferred to
an electronic case report form (eCRF) for remote storage
and monitoring. The following data were collected: patient
demographics, reason for pnfC1-INH administration (on
demand, prophylaxis, or other), pnfC1-INH dose, setting of
administration (healthcare facility or outside of a health-
care facility), concomitant medications, attack character-
istics (e.g., anatomic location, severity, potential triggers),
and adverse events (AEs). HAE attack data were collected
only for attacks treated with pnfC1-INH. Data about the
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use of C1-INH products other than Berinert were not col-
lected, nor were data collected on attacks that were
untreated or were treated with products other than Berinert.
Treatment outside of a healthcare setting included any
pnfC1-INH infusion administered by the subject, a family
member, friend, or other caregiver in a non-healthcare
setting (e.g., home). Treatment in a healthcare setting
included any pnfC1-INH infusion administered by a
healthcare professional (e.g., a physician or nurse) within a
healthcare institution (e.g., hospital or clinic).
AEs experienced by subjects within a 30-day period fol-
lowing treatment with pnfC1-INH were recorded regardless
of suspected causality to pnfC1-INH administration. For
each AE, investigators evaluated causality to pnfC1-INH
treatment based on clinical judgment and graded AE inten-
sity as mild (easily tolerated, no interference with daily
activities), moderate (causing some interference with daily
activities), or severe (incapacitating; unable to work or per-
form usual activities). AEs resulting in death, life-threaten-
ing circumstances, hospitalization, or persistent or
significant disability or incapacity were pre-defined as seri-
ous AEs (SAEs). Investigators engaged in subject follow-up
for all AEs until symptom resolution was achieved or the
condition was deemed chronic. Monitoring for suspected
viral transmissions was done per usual clinical practice, in
which investigators tested for viral transmission based upon
their medical judgment and local standard of medical care.
2.4 Data Analysis
Data were summarized using descriptive statistics, and select
outcomes were compared with findings from adult subjects
aged 17 to\65 years (hereafter, ‘younger adults’). Throm-
boembolic events (TEEs) were classified according to the
criteria of the Medical Dictionary for Regulatory Activities
(MedDRA) queries for embolic and thrombotic events. HAE
attacks and HAE attack signs and symptoms were not
recorded as AEs unless the attack also met SAE criteria (e.g.,
hospitalization). These were then dually reported as both
SAEs and HAE attacks. AEs reported without an intensity
grading were conservatively categorized as ‘severe’ and
included in both ‘severe’ and ‘missing’ groupings on data
tables. Events with missing causality were categorized by
convention as ‘related’. No efficacy analyses were per-
formed for acute HAE therapy. Prophylaxis findings for the
entire study population are to be reported separately.
3 Results
The registry enrolled 318 subjects who received at least
one pnfC1-INH dose. Of these, 27 (8.5 %) were aged
C65 years (all White; mean [standard deviation (SD)] age
70.5 [4.9] years, and predominantly from European sites)
(Table 1). Among older adult subjects, the registry cap-
tured 1701 pnfC1-INH infusions, which form the basis of
this report. A majority of the older adults (n = 25,
92.6 %) used pnfC1-INH for treatment of HAE attacks
(12 exclusively for this reason); 13 (48.1 %) used pnfC1-
INH for both attack treatment and prophylaxis, and two
(7.4 %) used pnfC1-INH for prophylaxis only and had no
pnfC1-INH-treated attacks recorded in the registry
(Table 2). Of the 1701 pnfC1-INH infusions, 841
(49.4 %) were recorded prospectively and 860 (50.6 %)
were recorded retrospectively. Of the 27 older adults, 21
(77.8 %) were using a variety of concomitant medications
(Table 3).
3.1 Characteristics of Hereditary Angioedema
(HAE) Attacks
A total of 1511 pnfC1-INH-treated HAE attacks were
recorded among 25 of the 27 (92.6 %) older adult registry
subjects. The number of attacks per subject (treated with
pnfC1-INH) ranged from 0 to 610. The majority of attacks
(88.0 %) occurred in the absence of an apparent trigger and
were categorized as spontaneous in origin. HAE attack
patterns by anatomic location were generally similar
between older adult subjects and the 252 younger adult
registry subjects, who experienced 9575 pnfC1-INH-
Table 1 Registry population demographics (subjects who received at
least one administration of pnfC1-INH)
Demographics Subjects C65 years (n = 27)
Agea (years)
Range 65–83













Data are presented as n (%) unless otherwise indicated
BMI body mass index, pnfC1-INH plasma-derived, highly-purified,
pasteurized, nanofiltered C1-inhibitor concentrate, SD standard
deviation
a At time of registry enrollment
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treated attacks (Fig. 1). With regard to anatomic location,
abdominal attacks were the most common among the older
adults, accounting for 33.8 % of all reported attacks and
occurring in 72.0 % of the older adults. A majority
(88.0 %) of the older adults experienced at least one attack
that was categorized as severe, although severe attacks
were a small proportion of all reported attacks (86 of 1511;
5.7 %) (Fig. 2).
3.2 pnfC1-INH Usage and Dosing
A majority of all pnfC1-INH infusions in older adult reg-
istry subjects (1511 of 1701; 88.8 %) were administered
for on-demand treatment of HAE attacks (Table 2). The
number of pnfC1-INH infusions per subject exhibited
substantial variability, ranging from 1 to 612. Among the
older adults, mean [SD] (8.8 [4.1] IU/kg) and median
(6.4 IU/kg) pnfC1-INH doses were lower than those
reported for the younger adults (12.9 [6.2] and 12.5 IU/kg,
respectively) (Table 4) and were also the lowest of any age
group in the registry [18].
The majority of pnfC1-INH infusions in the older adults
(94.7 %; 1611 of 1701) were recorded at European study
sites. Mean weight-based doses for the 20 European sub-
jects ranged from 5.9 to 20.3 IU/kg; the mean of the sub-
ject means was 12.0 IU/kg. For the seven US subjects,
mean doses per subject ranged from 15.6 to 22.0 IU/kg
(mean of the subject means 19.4 IU/kg).
3.3 Administration Setting
Ten (37 %) older adults had all of their pnfC1-INH infu-
sions administered in a healthcare setting; 11 (40.7 %) had
all infusions outside of a healthcare setting; five (18.5 %)
had infusions administered both in healthcare settings and
outside of a healthcare setting; and the setting was
unknown for one subject. Overall, a majority (94.6 %) of
all pnfC1-INH infusions in the older adults were given
outside of a healthcare setting and 4.4 % were given within
a healthcare setting (setting not recorded for 1.0 % of
infusions).
Of particular interest were instances in which pnfC1-
INH was administered outside of a healthcare setting (e.g.,
home) with a subsequent infusion(s) given in a healthcare
setting; the reasons for the change in setting were evaluated
Table 2 pnfC1-INH usage
Characteristics Subjects aged
C65 years
Subjects (n = 27)
Reason for pnfC1-INH use
On demand (attack treatment) only 12 (44.5)
Prophylaxis only 2 (7.4)
Both on demand treatment and prophylaxis 13 (48.1)
Administered pnfC1-INH outside of a healthcare
setting at least once
16 (59.3)
pnfC1-INH infusions (n = 1701)
Reason for pnfC1-INH use





Data are presented as n (%)
pnfC1-INH plasma-derived, highly-purified, pasteurized, nanofiltered
C1-inhibitor concentrate
Table 3 Concomitant medications used by C10 % of registry sub-
jects aged C65 yearsa
Concomitant medications by classb Subjects aged C65
years (n = 27)
Other HAE treatmentsc 21 (77.8)
Lipid-modifying agents 8 (29.6)
Calcium channel blockers 7 (25.9)
Diuretics 7 (25.9)
Drugs for acid-related disorders 7 (25.9)
Thyroid medication 7 (25.9)
Antithrombotic agents 6 (22.2)
Beta-blocking agents 6 (22.2)
Analgesics 5 (18.5)
Antibacterials 5 (18.5)
Diabetes drugs 4 (14.8)
Psycholepticsd 3 (11.1)
Agents acting on renin-angiotensin system 3 (11.1)
Psychoanalepticse 3 (11.1)
Data are presented as n (%)
ATC Anatomical Therapeutic Classification, HAE hereditary angioe-
dema, pnfC1-INH plasma-derived, highly-purified, pasteurized,
nanofiltered C1-Inhibitor concentrate, WHO World Health
Organization
a Any medications taken by a subject within 1 week before and after
pnfC1-INH use are regarded as concomitant therapy. If a subject had
multiple occurrences of medication, the subject is presented only once
per medication class
b WHO-recommended ATC classification system
c Includes icatibant, danazol, and drugs coded as antihemorrhagics by
WHO-recommended ATC classification (e.g., tranexamic acid)
d WHO-recommended ATC classification including antipsychotics,
anxiolytics, and hypnotics/sedatives
e WHO-recommended ATC classification including antidepressants,
psychostimulants, nootropics, anti-dementia drugs, and combinations
with psycholeptics
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whenever possible, with an interest in whether there were
issues relating to difficulty with self-infusion. Five older
adults had one or more such changes in administration
setting, most of which appeared to be related to patient
preference or already being at a medical facility when the
infusion was required. There were no recorded instances of
difficulty with pnfC1-INH infusion being the reason for
switching back to administration in a healthcare setting,
although reasons were not recorded in all cases.
3.4 Safety
In the entire registry, no AEs were identified in retro-
spective data; therefore, the safety analysis was based on
prospectively recorded infusions only (841 infusions in 23
older adults). A total of 19 AEs were reported in 8 of 23
(34.8 %) subjects with prospective infusion data, for an
overall rate of 0.83 events per subject and 0.02 events per
pnfC1-INH infusion. The majority (n = 13 [68.4 %]) of
AEs were categorized as mild in intensity, and no AEs
were considered related to pnfC1-INH administration.
These rates were similar to AE rates reported for younger
adults (0.91 per subject; 0.03 per infusion). Four SAEs
were reported in four older adults (prostatectomy; urinary
tract infection requiring hospitalization; fat embolism; and
GI bleeding), though none were considered related to
treatment with pnfC1-INH. There were no reports of
Fig. 1 Hereditary angioedema attack* patterns by anatomic location
for subjects aged C65 years compared with those for subjects aged 17
to\65 years. a Percentage of subjects experiencing at least one attack
per anatomic location. Percentages are based on the number of
subjects with at least one attack. Subjects were included only one time
for each anatomic location for which they experienced at least one
attack. Anatomic location data were missing for seven subjects aged
C65 years and 54 subjects aged 17 to\65 years. b Percentage of all
reported attacks* by anatomic location. Anatomic location data were
missing for 589 (39.0 %) of attacks in subjects aged C65 years and
1211 (12.6 %) of attacks in subjects aged 17 to \65 years. *Only
attacks treated with pnfC1-INH (Berinert). HAE hereditary
angioedema
Fig. 2 Severity of hereditary angioedema attacks*. a Per subject
(highest intensity reported) and b per attack among subjects aged
C65 years compared with subjects aged 17 to \65 years. a Per
subject, highest intensity reported. Attack density ratings were not
available in three (1.2 %) subjects aged 17 to\65 years. b Severity
distribution of all recorded attacks*. Attack intensity ratings were not
available for 280 (18.5 %) of attacks in subjects aged C65 years and
1267 (13.2 %) of attacks in subjects aged 17 to \65 years. *Only
attacks treated with pnfC1-INH (Berinert). For per subject reporting
of attack intensity, each subject is included in only one category based
on the maximum intensity attack
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hypersensitivity, anaphylaxis, or events consistent with
anaphylaxis. In accordance with the observational nature of
the registry, viral testing would have been conducted only
if considered necessary by the treating physician. There
were no reports of testing for blood-borne viral infection
conducted on any subject beyond baseline.
4 Discussion
Despite the lifelong nature of HAE and the growing
number of individuals aged C65 years entering the
healthcare system [20, 21], few published data are avail-
able on the treatment of HAE among patients C65 years
[12]. Research focused specifically on the older adult
population is important given that medical needs can differ
from those of younger adults [11]. By generating a con-
siderable volume of real-world data on the use of pnfC1-
INH to treat HAE in 27 older adults through 1701 pnfC1-
INH infusions, the findings from the Berinert Registry can
help fill this knowledge gap. To our knowledge, the reg-
istry data described here are the first to specifically evaluate
HAE attack characteristics and pnfC1-INH usage in
patients aged C65 years.
In examining HAE attack patterns and characteristics,
registry data for the older adult population generally par-
alleled those found among younger adults, with abdominal
attacks reported most frequently. Abdominal attacks in the
older adult population may be of particular interest, as
other GI events that may present as an acute abdomen (e.g.,
diverticulitis, intestinal perforation) tend to occur more
frequently in older individuals. Given the greater risk for
anesthesia in this population, the differential diagnosis,
inclusive of an abdominal HAE attack, is important. Fewer
older adults reported ever having experienced a laryngeal
attack. This may reflect a self-selection bias of this popu-
lation, given the absence of effective, readily available
HAE treatments decades ago and an ensuing higher
likelihood of death from laryngeal attacks during younger
years in this group. No triggering event was indicated for
the majority of attacks in older adults. Previous research
has identified similar attack patterns in general [22–25],
although the data reflected in the registry are limited to
attacks treated with pnfC1-INH. While at least one severe
attack was experienced by a majority (88.0 %) of older
adults, mild attacks constituted the largest percentage of all
documented attacks experienced within the older adult
population.
Even in the absence of regulatory approval of pnfC1-
INH for prophylactic treatment in the USA, half of older
adult registry subjects used pnfC1-INH for this purpose,
and two subjects received pnfC1-INH infusions exclusively
for prophylaxis. These findings are not unexpected in light
of consensus guidelines that recommend C1-INH for long-
or short-term prophylaxis [1, 13, 14, 26, 27] and clinical
data that support such use [28–38].
Current dosing recommendations for pnfC1-INH sug-
gest a dose of 20 IU/kg, regardless of patient age [39].
Prior to the current registry analysis, no known research
has described pnfC1-INH dosing in older adults. Among
older adult subjects in the registry, mean (8.8 IU/kg) and
median (6.4 IU/kg) weight-based pnfC1-INH doses were
notably lower than the recommended dose and also lower
than the mean and median weight-based doses reported for
252 younger adults in the registry (12.9 and 12.5 IU/kg,
respectively). Dosing patterns by geographic location
identified a trend of lower mean weight-based pnfC1-INH
doses for subjects in Europe relative to those in the USA, a
pattern that was also demonstrated for the entire registry
population, regardless of subject age [18]. Given that the
older adult subgroup was skewed heavily toward European
subjects, this presents another contributing factor to the
relatively low mean pnfC1-INH doses observed in this
subgroup as a whole.
Drug dosing in older adults is often approached con-
servatively given age-related physiologic changes that can
influence the pharmacokinetics and pharmacodynamics of
drug therapy [11, 40–43]. Physical changes related to
normal aging can be further complicated by the tendency of
older adults to manifest comorbid medical conditions
requiring concomitant therapy, as reflected by the majority
of subjects in this study who were using a variety of
medications along with pnfC1-INH. While there is no
reason to suspect altered disposition of a naturally occur-
ring therapeutic protein such as pnfC1-INH, the lower
mean doses reflected in this subset of registry patients
overall may reflect, at least in part, general attitudes about
drug usage and conservative dosing strategies in older
adults. These findings may also reveal consequences of
long-term experience with pnfC1-INH and personalized
dosage tailoring in these older patients, especially in
Table 4 pnfC1-INH dosing (all infusions, on demand and
prophylaxis)
pnfCI-INH administration Subject age group
C65 years 17 to\65 years
Number of infusions 1701 12,503
pnfC1-INH dose (IU/kg) per infusion
Meana (SD) 8.8 (4.1) 12.9 (6.2)
Median 6.4 12.5
Min, max 5.8, 24.4 3.4, 37.8
pnfC1-INH plasma-derived, highly-purified, pasteurized, nanofiltered
C1-Inhibitor concentrate, SD standard deviation
a Mean of subject means
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European markets where Berinert has been marketed for
several decades. Older adults are more likely to be retired
and possibly have less stress and more time to focus on
managing their disease.
Recent HAE consensus guidelines stress individualiza-
tion of therapy [13, 14, 27, 44, 45]. The variation in dosing
noted in the registry subjects seems to support an apparent
lack of ‘one dose fits all’ mindset, regardless of the specific
reasons for the lower doses reflected in this older adult
subset. While attack treatment efficacy data were not
captured as part of the registry, given this real-world set-
ting for pnfC1-INH, it could be assumed that dosing was
being tailored in these patients to maintain a satisfactory
level of benefit.
Considering the possibly higher-risk status of older
adults for drug-related problems due to the aforementioned
age-related conditions, determining the safety of real-world
use of pnfC1-INH in older patients is of particular interest,
and data from the registry confirm the overall safety of
pnfC1-INH within this population. Since retrospective data
are not a reliable source of safety information, safety
analyses in all age groups of the registry were conducted
for prospectively recorded events only. In the older adult
subgroup, the share of such data was 49.4 % (841 of 1701)
of all recorded infusions in 23 of 25 older adults, which
still constitutes a sizeable dataset. The observed AE rates
for older adult registry subjects were very low, both as
events per infusion and as events per subject, and were
similar to corresponding rates noted in younger adults in
the registry. None of the events were considered related to
pnfC1-INH, and there were no reports of TEEs, hyper-
sensitivity, or anaphylaxis. Viral transmission was not
prospectively assessed, but there was no evidence that any
patient was evaluated for suspected blood-borne viral ill-
ness during the registry. As previously noted, the majority
of older adults were also receiving concomitant medica-
tions during the time of pnfC1-INH administration, thus
highlighting safe use even in the presence of multiple
concomitant therapies.
Regarding setting of pnfC1-INH administration, recent
HAE expert guidelines consistently recommend training
and equipping patients for self- or home-based adminis-
tration of HAE medications, with treatment outside of a
healthcare setting providing more timely symptom relief,
mitigation of attack severity, lower healthcare costs, and
improved quality of life [8, 46–49]. For older adults, age-
related changes in physical or mental capacity and the
presence of medical comorbidities could be deterrents to
self-administration of intravenous medication. Research
has implicated several conditions, including osteoarthritis,
vision difficulties, and cognitive impairment, that may
negatively affect the elderly population’s self-management
of various at-home therapies [12, 43, 50]. However, the
registry findings support the safety and feasibility of
pnfC1-INH administration outside of a healthcare setting in
older adults with HAE. The vast majority (94.6 %) of
infusions in older adult registry subjects were administered
outside of the healthcare setting, and in 11 of the 27 older
adult subjects, all pnfC1-INH administration occurred in a
non-healthcare setting. Almost all pnfC1-INH infusions
administered outside of a healthcare setting in older adults
were reported as self-infusion; one infusion in one subject
was documented as given by a caregiver.
Subjects within the group receiving pnfC1-INH outside
of the healthcare setting had a wide range of number of
infusions (from 1 to 612), suggesting achievability of self-
administration regardless of attack frequency. This sub-
stantiates research identifying the skill of self-infusion as a
long-term competency in patients with HAE, and time
between attacks should not exclude patients from the
option of self-administration [49]. While four older adults
experienced at least one change in infusion setting from
non-healthcare setting to healthcare setting, there were no
recorded instances of difficulty with pnfC1-INH infusion
being the reason for any of these instances. The rates of
AEs remained low regardless of treatment setting and
corroborate reports indicating the high safety profile of
pnfC1-INH administration outside of a healthcare setting
[51, 52]. While every patient should be assessed individ-
ually before being considered a candidate for home-based
HAE treatment, the registry findings support the supposi-
tion that age itself should not preclude the option of self-
managed intravenous pnfC1-INH therapy. Numerous
studies have noted a marked increase in overall health and
treatment adherence when care is patient driven
[16, 41–43, 49, 50, 53]. During a stage of life when inde-
pendence is often threatened, the autonomy derived from
medication self-administration can foster a sense of control
in older adults, thereby improving morale and quality of
life.
The data from this registry analysis are subject to sev-
eral limitations. Inherent to the observational nature of the
study, there was no control group (other than younger age
groups) and no governance over pnfC1-INH usage or
dosing patterns, all of which were determined by the
treating physicians according to local standards of care. As
such, patterns of individual usage varied widely, including
the number of infusions per subject. Data were limited by
what was gathered by the treating physician, and AEs for
retrospective infusions were not reported. Furthermore,
only HAE attacks treated with pnfC1-INH were recorded.
The generalizability of the findings is limited by the racial
homogeneity of the population, the relatively small sample
size (although sizable for a rare disease subgroup), volun-
tary nature of participation. Finally, the nature of the reg-
istry data precluded analysis of attack treatment efficacy.
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5 Conclusions
These registry data support the safe use of pnfC1-INH in
older adults with HAE, with very low rates of AEs similar
to rates reported in younger adults in the registry, and none
considered related to treatment. Weight-based dosing of
pnfC1-INH was notably lower for older than for younger
adults, the reasons for which are unknown, nor was the
registry designed to evaluate efficacy ramifications of these
lower doses. The registry data support the safety and fea-
sibility of pnfC1-INH administration outside of a health-
care setting in older adults and document widespread
implementation of such practice in this demographic
subgroup.
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